(PharmaNewsWire.Com, August 05, 2021 ) According to the new market research report dPCR and qPCR market is projected to reach USD 7.6 billion by 2025 from USD 4.9 billion in 2020, at a CAGR of 9.0% between 2020 and 2025.
The growth of this market is driven majorly by the rising incidence of target infectious diseases and genetic disorders; technological advancements in PCR technologies; increasing investments, funds, and grants; increasing use of biomarker profiling for disease diagnostics; and successful completion of the Human Genome Project.
Based on products & services, the qPCR market is categorized into reagents and consumables, instruments and software & services. The qPCR reagents and consumables segment is expected to command the largest share of the qPCR products & services market in 2020, owing to the factors such as the expanding applications of qPCR (owing to its technological benefits over traditional PCR, such as real-time analysis and reduced analysis time), growing private-public funding for life science research, and the rising number of probe-based multiplex genetic analysis procedures (that require the analysis of low-volume gene samples).
Clinical application segment accounted for the largest share of qPCR market
Based on application, the market is categorized into clinical applications (Infectious Disease Testing, Oncology Testing, Blood Screening, Transplant Diagnostics and Other Clinical Applications), research applications and forensic applications. The clinical applications segment is estimated to dominate the qPCR applications market in 2020. The key factors driving the market growth of cclinical applications segment include the growing usage of qPCR in disease diagnosis, rising incidence of infectious and genetic diseases, and growing public emphasis on early & effective disease diagnosis & treatment.
Based on end users, the qPCR market is segmented into research laboratories and academic institutes, pharmaceutical and biotechnology companies, hospitals and diagnostic centers, clinical research organizations (CROs), and forensic laboratories. In 2019, the hospitals and diagnostic centers segment accounted for the largest share of the market. This can be attributed to the ongoing expansion of healthcare infrastructure across emerging countries, high prevalence of target diseases, increasing market availability of qPCR reagents for clinical diagnostic applications and growing awareness among end users related to the benefits offered by qPCR for clinical diagnosis.
North America accounted for the largest share of the dPCR market
North America accounted for the largest share of the dPCR and qPCR market, followed by Europe in 2019. The large share of the North American regional segment can be attributed to the increased adoption of innovative and novel genomic analysis products (including advanced qPCR and dPCR products), availability of R&D funding for genomic research (coupled with the robust research infrastructure in the region), expanding use of PCR techniques in clinical diagnostics & forensics, and early commercialization of qPCR/dPCR products compared to other regions.
The prominent players operating in the dPCR and qPCR market are Thermo Fisher Scientific (US), Bio-Rad Laboratories Inc. (US), and F. Hoffmann-La Roche, Ltd. (Switzerland).
Some key developments in the PCR industry are mentioned below:
> In 2020, Bio-Rad received FDA emergency use authorization for the Droplet Digital PCR SARS-CoV-2 Test Kit. > To combat the COVID-19 outbreak, Thermo Fisher developed several PCR kits and assays for diagnostics and research applications. The company received the US FDA emergency use authorization (EUA) for SARS‑CoV‑2 multiplex real-time PCR test and also launched AcroMetrix Coronavirus 2019 (COVID-19) RNA Control in 2020. > In 2020, bioMérieux S.A. received the CE Mark approval for SARS-CoV-2 R-GENE tests to include saliva specimens. The company also received emergency use authorization for the BioFire COVID-19 test. > In 2020, Danaher Corporation received the US FDA Emergency Use Authorization (EUA) for the Xpert Xpress SARS-CoV-2 test.
Contact: Mr. Aashish Mehra MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 Email: sales@marketsandmarkets.com
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
